ENA
October 26, 2022
EORTC-NCI-AACR Symposium (ENA), October 26-28, 2022
Year
2022
Target
RVU120 (CDK8/CDK19), RVU 305 (PRMT5)
Assets in this page
Download assets
- pdf file
Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Download